{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:41:23Z","timestamp":1793209283106,"version":"4.5.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Resistance to Bruton tyrosine kinase (BTK) inhibitors remains a major clinical challenge in B-cell lymphomas and often occurs in the absence of BTK or PLCG2 mutations. Here, we investigated nongenetic mechanisms of ibrutinib resistance in marginal zone lymphoma (MZL) and their broader therapeutic implications. Continuous ibrutinib exposure generated a resistant MZL model that showed cross-resistance to BTK inhibitors and degraders, without evidence of multidrug resistance or genetic alterations. Integrated transcriptomic, epigenetic, and proteomic analyses revealed extensive reprogramming, including the activation of phosphatidylinositol 3-kinase (PI3K)\/AKT, MAPK, and MYC pathways, repression of apoptosis and oxidative phosphorylation, and a prominent cytokine-secretory phenotype. Interleukin-16 (IL-16) emerged as a central mediator of resistance. IL-16 was transcriptionally upregulated, actively secreted, and sufficient to induce ibrutinib resistance across multiple CD9+ models of MZL, mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and activated B-cell\u2013like diffuse large B-cell lymphoma. Serum IL-16 levels were elevated in patients with ibrutinib-refractory CLL without BTK\/PLCG2 mutations. Mechanistically, IL-16 engaged CD9-enriched membrane microdomains to activate PI3K\u03b4, thereby sustaining AKT and extracellular signal-regulated kinase signaling, stabilizing MYC, inducing NF-\u03baB\u2013dependent programs, and upregulating antiapoptotic effectors, including BFL1 (BCL2A1). Pharmacological or genetic disruption of the IL-16\/CD9\/PI3K axis restored sensitivity to BTK inhibitors and R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine [Oncovin], and prednisone) and abrogated IL-16\u2013induced signaling in primary CLL samples. In conclusion, an IL-16\/CD9-driven, epigenetically regulated survival pathway represents one possible mechanism of resistance to BTK inhibitors and chemoimmunotherapy, supporting therapeutic targeting of this axis in refractory B-cell lymphomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029956","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:20:11Z","timestamp":1780075211000},"page":"1312-1327","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3123-6203","authenticated-orcid":false,"given":"Alberto J.","family":"Arribas","sequence":"first","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"},{"name":"2Swiss Institute of Bioinformatics, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9551-7122","authenticated-orcid":false,"given":"Eleonora","family":"Cannas","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6704-9755","authenticated-orcid":false,"given":"Giulio","family":"Sartori","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Guidetti","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4606-0637","authenticated-orcid":false,"given":"Luciano","family":"Cascione","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"},{"name":"2Swiss Institute of Bioinformatics, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Napoli","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Forestieri","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fuzio","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Pesenti","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tarantelli","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Spriano","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-5957","authenticated-orcid":false,"given":"Antonella","family":"Zucchetto","sequence":"additional","affiliation":[{"name":"3Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca M.","family":"Rossi","sequence":"additional","affiliation":[{"name":"3Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Bruscaggin","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8488-5306","authenticated-orcid":false,"given":"Manuel","family":"Castro de Moura","sequence":"additional","affiliation":[{"name":"4Josep Carreras Leukaemia Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Jovic","sequence":"additional","affiliation":[{"name":"5Institute for Research in Biomedicine, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-386X","authenticated-orcid":false,"given":"Andrea","family":"Raimondi","sequence":"additional","affiliation":[{"name":"5Institute for Research in Biomedicine, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Bordone","family":"Pittau","sequence":"additional","affiliation":[{"name":"6Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodovico","family":"Terzi di Bergamo","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Ye","sequence":"additional","affiliation":[{"name":"7Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[{"name":"6Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"},{"name":"8Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaacov","family":"Ben-David","sequence":"additional","affiliation":[{"name":"9State Key Laboratory for Discovery and Utilization of Functional Component in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, People's Republic of China"},{"name":"10The Natural Products Research Center of Guizhou Province, Guiyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1990-8804","authenticated-orcid":false,"given":"Qiang","family":"Pan-Hammarstr\u00f6m","sequence":"additional","affiliation":[{"name":"7Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0399-689X","authenticated-orcid":false,"given":"Federico","family":"Simonetta","sequence":"additional","affiliation":[{"name":"11Division of Haematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland"},{"name":"12Translational Research Center for Oncohematology, Department of Medicine and Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Stussi","sequence":"additional","affiliation":[{"name":"6Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-6109","authenticated-orcid":false,"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"},{"name":"6Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valter","family":"Gattei","sequence":"additional","affiliation":[{"name":"3Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"13Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4490-6093","authenticated-orcid":false,"given":"Manel","family":"Esteller","sequence":"additional","affiliation":[{"name":"4Josep Carreras Leukaemia Research Institute, Barcelona, Spain"},{"name":"14Centro de Investigacion Biomedica en Red Cancer, Madrid, Spain"},{"name":"15Institucio Catalana de Recerca i Estudis Avan\u00e7ats, Barcelona, Spain"},{"name":"16Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"},{"name":"6Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-8983","authenticated-orcid":false,"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[{"name":"1Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"},{"name":"6Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"13","key":"2026090311220232000_bib1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood.2020006783","article-title":"Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies","volume":"138","author":"Stephens","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2026090311220232000_bib2","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026090311220232000_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"2026090311220232000_bib4","doi-asserted-by":"crossref","first-page":"103532","DOI":"10.1016\/j.autrev.2024.103532","article-title":"Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases","volume":"23","author":"De Bondt","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"6","key":"2026090311220232000_bib5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2026090311220232000_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2643-3230.BCD-21-0063","article-title":"Overcoming acquired epigenetic resistance to BTK inhibitors","volume":"2","author":"Shaffer","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"2026090311220232000_bib7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1535-7163.MCT-23-0068","article-title":"ERBB4-mediated signaling is a mediator of resistance to PI3K and BTK inhibitors in B-cell lymphoid neoplasms","volume":"23","author":"Arribas","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2026090311220232000_bib8","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood.2021012386","article-title":"Genetic and phenotypic attributes of splenic marginal zone lymphoma","volume":"139","author":"Bonfiglio","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026090311220232000_bib9","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.3324\/haematol.2021.279957","article-title":"Resistance to PI3Kdelta inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6\/PDGFRA axis","volume":"107","author":"Arribas","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"2026090311220232000_bib10","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.3324\/haematol.2019.227215","article-title":"Targeting CD205 with the antibody drug conjugate MEN1309\/OBT076 is an active new therapeutic strategy in lymphoma models","volume":"105","author":"Gaudio","year":"2020","journal-title":"haematol"},{"issue":"10","key":"2026090311220232000_bib11","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.3324\/haematol.2023.284197","article-title":"Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy","volume":"109","author":"Tarantelli","year":"2024","journal-title":"Haematologica"},{"issue":"5","key":"2026090311220232000_bib12","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0002-9440(10)65411-9","article-title":"7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma","volume":"154","author":"Mateo","year":"1999","journal-title":"Am J Pathol"},{"issue":"5","key":"2026090311220232000_bib13","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2004-10-3898","article-title":"Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis","volume":"106","author":"Ruiz-Ballesteros","year":"2005","journal-title":"Blood"},{"issue":"15","key":"2026090311220232000_bib14","doi-asserted-by":"crossref","first-page":"e120798","DOI":"10.1172\/jci.insight.120798","article-title":"IL-16\/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation","volume":"3","author":"Smith","year":"2018","journal-title":"JCI Insight"},{"issue":"13","key":"2026090311220232000_bib15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jnci\/djs257","article-title":"Role of interleukin 16 in multiple myeloma","volume":"104","author":"Atanackovic","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2026090311220232000_bib16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1158\/2767-9764.CRC-22-0477","article-title":"IOA-244 is a non-ATP-competitive, highly selective, tolerable PI3K delta inhibitor that targets solid tumors and breaks immune tolerance","volume":"3","author":"Johnson","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"3","key":"2026090311220232000_bib17","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1182\/blood-2011-02-339556","article-title":"Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets","volume":"119","author":"Arribas","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2026090311220232000_bib18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/modpathol.2012.220","article-title":"Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling","volume":"26","author":"Arribas","year":"2013","journal-title":"Mod Pathol"},{"issue":"22","key":"2026090311220232000_bib19","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"2026090311220232000_bib20","doi-asserted-by":"crossref","first-page":"110713","DOI":"10.1016\/j.celrep.2022.110713","article-title":"A single-cell atlas of diffuse large B cell lymphoma","volume":"39","author":"Ye","year":"2022","journal-title":"Cell Rep"},{"issue":"1","key":"2026090311220232000_bib21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41467-019-14081-6","article-title":"Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL","volume":"11","author":"Rendeiro","year":"2020","journal-title":"Nat Commun"},{"issue":"17","key":"2026090311220232000_bib22","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2026090311220232000_bib23","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2013-06-508937","article-title":"Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens","volume":"122","author":"Masque-Soler","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2026090311220232000_bib24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.14817","article-title":"Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study","volume":"182","author":"Cascione","year":"2018","journal-title":"Br J Haematol"},{"issue":"18","key":"2026090311220232000_bib25","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1158\/0008-5472.CAN-15-0405","article-title":"Tumor-promoting effects of myeloid-derived suppressor cells are potentiated by hypoxia-induced expression of miR-210","volume":"75","author":"Noman","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"2026090311220232000_bib26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s13046-021-02159-3","article-title":"ASB2 is a direct target of FLI1 that sustains NF-\u03baB pathway activation in germinal center-derived diffuse large B-cell lymphoma","volume":"40","author":"Sartori","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026090311220232000_bib27","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.2147\/JIR.S500822","article-title":"FLI1 induces plaque psoriasis and its inhibition attenuates disease progression","volume":"18","author":"Hu","year":"2025","journal-title":"J Inflamm Res"},{"issue":"10","key":"2026090311220232000_bib28","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.2024026672","article-title":"Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors","volume":"145","author":"Tam","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2026090311220232000_bib29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/jir.2006.26.511","article-title":"Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases","volume":"26","author":"Glass","year":"2006","journal-title":"J Interferon Cytokine Res"},{"issue":"4","key":"2026090311220232000_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1034\/j.1600-0625.2000.009004248.x","article-title":"IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression","volume":"9","author":"Asadullah","year":"2000","journal-title":"Exp Dermatol"},{"issue":"8","key":"2026090311220232000_bib31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0145-2126(01)00192-8","article-title":"Relationship between CD4(+)\/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16","volume":"26","author":"Koike","year":"2002","journal-title":"Leuk Res"},{"issue":"2","key":"2026090311220232000_bib32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ajh.10444","article-title":"Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity","volume":"75","author":"Alexandrakis","year":"2004","journal-title":"Am J Hematol"},{"key":"2026090311220232000_bib33","doi-asserted-by":"crossref","first-page":"107315","DOI":"10.1016\/j.leukres.2023.107315","article-title":"Elevated expression of interleukin 16 in chronic lymphocytic leukemia is associated with disease burden and abnormal immune microenvironment","volume":"131","author":"Wu","year":"2023","journal-title":"Leuk Res"},{"issue":"1","key":"2026090311220232000_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41419-023-06381-z","article-title":"Neutralizing IL-16 enhances the efficacy of targeting Aurora-A therapy in colorectal cancer with high lymphocyte infiltration through restoring anti-tumor immunity","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis"},{"issue":"1","key":"2026090311220232000_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood-2005-03-1312","article-title":"Human and mouse mast cells use the tetraspanin CD9 as an alternate interleukin-16 receptor","volume":"107","author":"Qi","year":"2006","journal-title":"Blood"},{"key":"2026090311220232000_bib36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fimmu.2018.00863","article-title":"Tetraspanin CD9: a key regulator of cell adhesion in the immune system","volume":"9","author":"Reyes","year":"2018","journal-title":"Front Immunol"},{"key":"2026090311220232000_bib37","doi-asserted-by":"crossref","first-page":"1140738","DOI":"10.3389\/fonc.2023.1140738","article-title":"Prognostic value and multifaceted roles of tetraspanin CD9 in cancer","volume":"13","author":"Ondru\u0161\u0161ek","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"2026090311220232000_bib38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3892\/or.2021.8091","article-title":"Interaction between CD9 and PI3K-p85 activates the PI3K\/AKT signaling pathway in B-lineage acute lymphoblastic leukemia","volume":"46","author":"Shi","year":"2021","journal-title":"Oncol Rep"},{"issue":"46","key":"2026090311220232000_bib39","doi-asserted-by":"crossref","first-page":"30537","DOI":"10.1074\/jbc.273.46.30537","article-title":"CD19 is linked to the integrin-associated tetraspans CD9, CD81, and CD82","volume":"273","author":"Horvath","year":"1998","journal-title":"J Biol Chem"},{"issue":"3","key":"2026090311220232000_bib40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00262-003-0477-5","article-title":"Tetraspanins connect several types of Ig proteins: IgM is a novel component of the tetraspanin web on B-lymphoid cells","volume":"53","author":"Le Naour","year":"2004","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2026090311220232000_bib41","first-page":"425","article-title":"Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large B-cell lymphomas and regulates the pro-tumor microenvironment","volume":"110","author":"Guan","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"2026090311220232000_bib42","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41467-025-56323-w","article-title":"Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's macroglobulinemia","volume":"16","author":"Sklavenitis-Pistofidis","year":"2025","journal-title":"Nat Commun"},{"issue":"5","key":"2026090311220232000_bib43","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ijc.20614","article-title":"High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia","volume":"113","author":"Morales","year":"2005","journal-title":"Int J Cancer"},{"issue":"3-4","key":"2026090311220232000_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.18632\/oncoscience.402","article-title":"BFL-1 expression determines the efficacy of venetoclax in MYC+\/BCL2+ double hit lymphoma","volume":"5","author":"Esteve-Arenys","year":"2018","journal-title":"Oncoscience"},{"issue":"1","key":"2026090311220232000_bib45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/10428194.2022.2140282","article-title":"Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs","volume":"64","author":"Park","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2026090311220232000_bib46","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cellsig.2009.03.007","article-title":"Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation","volume":"21","author":"Carsetti","year":"2009","journal-title":"Cell Signal"},{"issue":"24","key":"2026090311220232000_bib47","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"516","key":"2026090311220232000_bib48","doi-asserted-by":"crossref","first-page":"eaax2863","DOI":"10.1126\/scitranslmed.aax2863","article-title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response","volume":"11","author":"Sharon","year":"2019","journal-title":"Sci Transl Med"},{"issue":"4","key":"2026090311220232000_bib49","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"},{"key":"2026090311220232000_bib50","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cyto.2018.05.038","article-title":"Ablation of the CD9 receptor in human lung cancer cells using CRISPR\/Cas alters migration to chemoattractants including IL-16","volume":"111","author":"Blake","year":"2018","journal-title":"Cytokine"},{"issue":"2","key":"2026090311220232000_bib51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jcp.24441","article-title":"Regulation of cellular processes by interleukin-16 in homeostasis and cancer","volume":"229","author":"Richmond","year":"2014","journal-title":"J Cell Physiol"},{"issue":"10","key":"2026090311220232000_bib52","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026090311220232000_bib53","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.4049\/jimmunol.1600915","article-title":"Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia","volume":"197","author":"Ten Hacken","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"2026090311220232000_bib54","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1186\/s12885-019-6057-7","article-title":"Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"2026090311220232000_bib55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/onc.2017.339","article-title":"ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma","volume":"37","author":"Yun","year":"2018","journal-title":"Oncogene"},{"issue":"24","key":"2026090311220232000_bib56","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.1182\/bloodadvances.2023012291","article-title":"PI3Kdelta activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas","volume":"8","author":"Arribas","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026090311220232000_bib57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating tumor DNA in lymphoma: principles and future directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/10\/1312\/2541967\/blood_bld-2025-029956-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/10\/1312\/2541967\/blood_bld-2025-029956-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:22:13Z","timestamp":1788448933000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/10\/1312\/568799\/IL-16-production-is-a-mechanism-of-resistance-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029956","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,3]]},"published":{"date-parts":[[2026,9,3]]}}}